文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

组织学证实的急性嗜酸性心肌炎自然史研究

Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis.
PubMed 文献 · Circulation · 2026-02-06

该国际多中心回顾性队列研究纳入156例组织学证实的急性嗜酸性心肌炎患者,中位年龄48岁,仅57.4%有外周血嗜酸性粒细胞增多。年龄增大、入院时左心室射血分数降低及未接受免疫抑制治疗是死亡或心脏移植的独立预测因素。

要点

  • 急性嗜酸性心肌炎可无外周血嗜酸性粒细胞增多,确诊需心内膜心肌活检。
  • 院内死亡或心脏移植率达14.7%,1年和3年死亡或心脏移植率分别为19.0%和23.8%。
  • 住院期间免疫抑制治疗与无心脏移植生存相关。

核心结论

  • 急性嗜酸性心肌炎常无外周血嗜酸性粒细胞增多,院内及中期死亡或心脏移植率高。
  • 住院期间免疫抑制治疗与无心脏移植生存相关,但仍需个体化免疫抑制方案改善预后。

研究设计与样本

  • 国际多中心回顾性队列研究,53个中心在1992至2023年间筛查193例组织学证实的急性嗜酸性心肌炎患者。
  • 排除数据不足10例、症状持续超过30天19例及组织学诊断复核未确认8例后,最终纳入156例。

主要发现

  • 中位发病年龄48岁(四分位距34-59岁),男性占67.3%,仅2例(1.3%)为16岁及以下儿科病例。
  • 主要表现症状为呼吸困难(75.6%)、发热(61.3%)和胸痛(53.2%)。
  • 外周血嗜酸性粒细胞增多仅占57.4%,中位细胞计数630个/μL。
  • 入院时中位左心室射血分数为32%(四分位距25%-48%)。
  • 最常见相关疾病为嗜酸性肉芽肿性多血管炎(22.4%)和超敏反应型(14.1%),特发性/未明确型占44.9%,其他原因占18.6%。

关键数值与推荐

  • 院内死亡或需心脏移植共23例(14.7%;22例死亡和1例心脏移植),尽管43.6%接受临时机械循环支持、92.9%接受免疫抑制治疗。
  • 估计1年和3年死亡或心脏移植率分别为19.0%和23.8%。
  • 年龄增大、入院时左心室射血分数降低及住院期间未接受免疫抑制治疗是死亡或心脏移植的独立预测因素。
  • 3年时超敏反应型死亡或心脏移植发生率(46.1%)高于嗜酸性肉芽肿性多血管炎相关型(13.1%),但差异无统计学意义(P=0.15)。

临床怎么用

  • 对疑似急性嗜酸性心肌炎患者,不应仅依赖外周血嗜酸性粒细胞增多,需行心内膜心肌活检确诊。
  • 住院期间应考虑免疫抑制治疗,并根据病因制定个体化方案。
  • 对年龄较大、入院左心室射血分数降低的患者应加强监测和积极治疗。

局限性

  • 回顾性研究设计可能存在选择偏倚和信息偏倚。
  • 部分患者因数据不足、症状持续时间过长或诊断未复核确认而被排除。
  • 超敏反应型与嗜酸性肉芽肿性多血管炎相关型之间的预后比较未达统计学显著性,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No large registries of patients with acute eosinophilic myocarditis (EM) are available. However, EM is perceived as a cardiac disease with high mortality, affecting mainly young and middle-aged adults according to small series and case reports. Awareness of the clinical presentation, associated systemic conditions, treatments, and outcomes of this uncommon condition is an unmet need. METHODS: In this international, multicenter, retrospective cohort study, 53 centers screened 193 patients with histologically proven acute EM between 1992 and 2023. After the exclusion of patients with insufficient data (n=10), symptoms lasting >30 days (n=19), or histological diagnosis not confirmed after review (n=8), 156 patients were included. RESULTS: Median age at presentation was 48 years (first to third quartile, 34-59 years) with male predominance (67.3%), and only 2 were pediatric cases (≤16 years of age; 1.3%). The main signs and symptoms at presentation were dyspnea (75.6%), fever (61.3%), and chest pain (53.2%). Unexpectedly, peripheral eosinophilia was reported in only 57.4% of cases, with a median cell count of 630 eosinophils/μL. The median left ventricular ejection fraction at presentation was 32% (first to third quartile, 25%-48%). The disorders most frequently associated with EM were eosinophilic granulomatosis with polyangiitis (22.4% of cases) and hypersensitivity forms (14.1%). Idiopathic/undefined forms accounted for 44.9% of cases, and miscellaneous causes accounted for 18.6%. In-hospital death or need for heart transplantation (HTx) occurred in 23 patients (14.7%; 22 deaths and 1 HTx), despite 43.6% being treated with temporary mechanical circulatory support and 92.9% being treated with immunosuppressive agents. Estimated rates of death or HTx at 1 and 3 years were 19.0% and 23.8%. Increased age, decreased left ventricular ejection fraction on admission, and no immunosuppressive therapy during hospitalization were independent predictors of death or HTx. A nonsignificant higher occurrence of deaths or HTx was observed in the hypersensitivity form (46.1%) compared with the eosinophilic granulomatosis with polyangiitis-associated form (13.1%) at 3 years (P=0.15). CONCLUSIONS: Acute EM can often present without peripheral eosinophilia, and rates of in-hospital and midterm mortality or HTx are high. Endomyocardial biopsy is required to reach the final diagnosis of EM because relying on peripheral eosinophilia can lead to missing diagnosis. In-hospital immunosuppression is associated with HTx-free survival, although tailored immunosuppressive therapies are needed to improve outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06447935.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Ammirati E, Palazzini M, Lehtonen J, et al. Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. Circulation. 2026. PMID: 41645905. doi:10.1161/CIRCULATIONAHA.125.074797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。